Young Mania Rating Scale (YMRS)

The Young Mania Rating Scale (YMRS) is the most widely used clinician-administered rating scale for assessing the severity of manic symptoms in patients with bipolar disorder. Developed by Robert Young and colleagues in 1978 at the University of Pittsburgh, the YMRS has become the gold standard outcome measure in clinical trials of antimanic agents and is extensively used in clinical practice for monitoring treatment response in manic and hypomanic episodes.

Bipolar disorder is a chronic psychiatric condition characterized by recurrent episodes of mania, hypomania, and depression. Manic episodes represent the most acute and potentially dangerous phase of the illness, frequently requiring hospitalization and associated with significant functional impairment, psychosocial disruption, and medical complications. Accurate quantification of manic symptom severity is essential for clinical decision-making and treatment monitoring.

The YMRS comprises 11 items that assess the core features of mania as defined by diagnostic criteria. Seven items are rated on a 5-point scale (0-4): elevated mood, increased motor activity, sexual interest, sleep disturbance, thought disorder, appearance, and insight. Four items are rated on a 9-point scale (0-8) to reflect their greater potential severity: irritability, speech, thought content, and disruptive-aggressive behavior. This weighted scoring acknowledges that these four symptoms have a wider range of clinical severity and greater impact on functioning.

The total score ranges from 0 to 60. Clinical convention classifies scores as follows: less than 13 indicates remission or minimal symptoms, 13-19 suggests hypomania, 20-25 indicates moderate mania, and 26 or above represents severe mania. These cutoff points were established through clinical consensus and validated against global clinical impression ratings in multiple studies.

Psychometric evaluation has demonstrated excellent inter-rater reliability (intraclass correlation coefficients 0.93-0.95), good internal consistency (Cronbach's alpha 0.70-0.85), and high sensitivity to change during treatment. The YMRS has been shown to discriminate between manic, hypomanic, mixed, and euthymic states, and correlates strongly with other mania severity measures and clinician global impressions.

In clinical trials, the YMRS serves as the primary outcome measure for evaluating antimanic efficacy. A 50% reduction in total score is typically defined as treatment response, while a total score below 12 indicates remission. Regulatory agencies including the FDA accept YMRS as the primary efficacy endpoint for approval of antimanic medications, underscoring its scientific credibility and clinical utility.

The YMRS is designed to be administered by a trained clinician through a structured interview lasting approximately 15-30 minutes. Ratings are based on the patient's subjective report and the clinician's behavioral observations during the interview, with the past 48 hours as the assessment timeframe. Training in YMRS administration is recommended to ensure reliable and valid scoring across raters.

This calculator implements the standard YMRS scoring with established severity classifications, providing clinicians with a validated tool for quantifying manic symptom severity and monitoring treatment response in bipolar disorder.